This is not the most recent version of the article. View current version (16 NOV 2016)

Intervention Review

You have free access to this content

Pharmacotherapies for sleep disturbances in Alzheimer's disease

  1. Jenny McCleery1,*,
  2. Daniel A. Cohen2,
  3. Ann L Sharpley3

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 21 MAR 2014

Assessed as up-to-date: 31 MAR 2013

DOI: 10.1002/14651858.CD009178.pub2


How to Cite

McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD009178. DOI: 10.1002/14651858.CD009178.pub2.

Author Information

  1. 1

    Oxford Health NHS Foundation Trust, Banbury, Oxfordshire, UK

  2. 2

    Division of Sleep Medicine, Research Fellow in Sleep and Circadian Neurobiology, Boston, MA, USA

  3. 3

    Oxford University, Department of Psychiatry, Oxford, UK

*Jenny McCleery, Oxford Health NHS Foundation Trust, Elms Centre, Oxford Road, Banbury, Oxfordshire, OX16 9AL, UK. jenny.mccleery@oxfordhealth.nhs.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 21 MAR 2014

SEARCH

This is not the most recent version of the article. View current version (16 NOV 2016)

[Figure 1]
Figure 1. Study flow diagram
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Melatonin versus placebo, outcome: 1.1 total night-time sleep time (minutes)
[Figure 5]
Figure 5. Forest plot of comparison: 1 Melatonin versus placebo, outcome: 1.5 ratio of daytime sleep to night-time sleep
[Analysis 1.1]
Analysis 1.1. Comparison 1 Melatonin versus placebo: efficacy, Outcome 1 total nocturnal sleep time (minutes).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Melatonin versus placebo: efficacy, Outcome 2 sleep efficiency.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Melatonin versus placebo: efficacy, Outcome 3 nocturnal time awake (minutes).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Melatonin versus placebo: efficacy, Outcome 4 number of night-time awakenings.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Melatonin versus placebo: efficacy, Outcome 5 ratio of daytime sleep to night-time sleep.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Melatonin versus placebo: efficacy, Outcome 6 carer-rated sleep quality, change from baseline.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Melatonin versus placebo: efficacy, Outcome 7 MMSE, change from baseline.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Melatonin versus placebo: efficacy, Outcome 8 ADAS-cog, change from baseline.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Melatonin versus placebo: efficacy, Outcome 9 ADL, change from baseline.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Melatonin versus placebo: safety, Outcome 1 number of adverse event reports per person.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Melatonin versus placebo: safety, Outcome 2 adverse event severity.